Casdin Capital, LLC Intellia Therapeutics, Inc. Transaction History
Casdin Capital, LLC
- $1.15 Billion
- Q2 2024
A detailed history of Casdin Capital, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 2,000,000 shares of NTLA stock, worth $42 Million. This represents 3.88% of its overall portfolio holdings.
Number of Shares
2,000,000
Previous 1,875,000
6.67%
Holding current value
$42 Million
Previous $51.6 Million
13.22%
% of portfolio
3.88%
Previous 4.17%
Shares
6 transactions
Others Institutions Holding NTLA
# of Institutions
326Shares Held
88.8MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$244 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$202 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$191 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$101 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$91.7 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.6B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...